Informed Consent for Ketamine Therapy: Best Practices and Legal Considerations

Informed consent is both an ethical obligation and a legal requirement that serves as the foundation of the therapeutic relationship. For ketamine therapy, the consent process carries unique considerations including off-label use disclosure, novel treatment status, and the altered states patients will experience. This comprehensive guide examines best practices for informed consent that protect patients through transparency and protect practitioners through documentation.

The Purpose and Principles of Informed Consent

Ethical Foundations

Informed consent embodies core bioethical principles:

Autonomy: Patients have the right to make informed decisions about their own healthcare based on accurate information and free from coercion.

Beneficence: Healthcare providers have an obligation to act in patients' best interests, which includes ensuring they understand their options.

Non-maleficence: Patients must understand potential risks to make decisions that avoid harm to themselves.

Justice: All patients deserve equal access to information necessary for healthcare decisions.

Legal Requirements

Informed consent serves multiple legal functions:

| Function | Description | |----------|-------------| | Authorization | Legal permission to proceed with treatment | | Documentation | Evidence that consent process occurred | | Defense | Protection against battery/negligence claims | | Standard of care | Demonstrates adherence to professional standards |

Elements Required by Law: Most jurisdictions require consent to include:

• Nature of the proposed treatment
• Risks and benefits
• Alternatives, including no treatment
• Opportunity to ask questions
• Voluntary agreement

Consent as Process, Not Event

Common Misconception: Informed consent is a form to be signed.

Reality: Informed consent is an ongoing dialogue between provider and patient. The signed document merely memorializes that the process occurred.

Process Elements:

1. Information exchange
2. Patient comprehension
3. Voluntary decision-making
4. Documentation
5. Ongoing consent verification

Required Disclosures for Ketamine Therapy

Diagnosis and Treatment Rationale

Required Elements:

• Patient's diagnosis
• How ketamine addresses this condition
• Why ketamine is being recommended
• Prior treatments attempted
• Evidence supporting ketamine for this indication

Sample Language: "You have been diagnosed with treatment-resistant major depressive disorder, meaning you have tried multiple antidepressant medications without adequate relief. Ketamine has been shown in research studies to produce rapid improvement in depression symptoms in many patients who haven't responded to traditional treatments. We are recommending ketamine because [specific rationale for this patient]."

Treatment Description

Required Elements:

• Route of administration (IV, IM, intranasal, sublingual)
• Dose range and how determined
• Treatment duration and frequency
• What patient will experience
• Setting and monitoring
• Number of treatments recommended

Sample Language (IV): "We will administer ketamine through an intravenous (IV) line in your arm. The dose will be approximately 0.5 mg per kilogram of your body weight, infused slowly over 40 minutes. During the infusion, you will be in a comfortable reclining position with continuous monitoring of your blood pressure, heart rate, and oxygen levels. You will likely experience altered sensations and perceptions, which we will discuss in detail."

Off-Label Use Disclosure

Critical Importance: With the exception of esketamine (Spravato) for treatment-resistant depression and acute suicidal ideation, ketamine use for psychiatric conditions is off-label.

Required Disclosure Elements:

• FDA approval status
• What "off-label" means
• Why this is acceptable medical practice
• Evidence supporting the off-label use
• Implications for insurance coverage

Sample Language: "Ketamine was originally approved by the FDA as an anesthetic. Using ketamine to treat depression is considered 'off-label' use, meaning it is not specifically FDA-approved for this purpose. However, off-label prescribing is legal, common in medicine, and supported by substantial research evidence showing ketamine's effectiveness for depression. Many treatments you may have used before were also prescribed off-label. Because this is an off-label use, your insurance may not cover the cost of treatment."

For Esketamine (Spravato): "Esketamine nasal spray (Spravato) has been specifically approved by the FDA for treatment-resistant depression [and/or acute suicidal ideation in adults with MDD]. As an FDA-approved treatment, it may be covered by your insurance, though prior authorization is typically required."

Risk Disclosure

Common Side Effects

Required Disclosure: Side effects occurring in >10% of patients

| Side Effect | Frequency | Description | |-------------|-----------|-------------| | Dissociation | Very common (>25%) | Feeling detached from body or surroundings | | Dizziness | Very common (>25%) | Lightheadedness, unsteadiness | | Nausea | Common (10-25%) | Stomach upset, possible vomiting | | Sedation | Common (10-25%) | Drowsiness, fatigue | | Headache | Common (10-25%) | Usually mild, self-limiting | | Elevated BP | Common (10-25%) | Temporary increase in blood pressure | | Elevated HR | Common (10-25%) | Temporary increase in heart rate | | Perceptual changes | Common (10-25%) | Visual distortions, altered sensations | | Anxiety | Occasional (5-10%) | May occur during treatment |

Serious but Rare Risks

| Risk | Frequency | Description | |------|-----------|-------------| | Hypertensive crisis | Rare (<1%) | Severe blood pressure elevation | | Respiratory depression | Rare (<1%) | Usually at higher doses | | Prolonged psychotic symptoms | Rare (<1%) | More likely with predisposition | | Severe allergic reaction | Very rare (<0.1%) | Anaphylaxis | | Laryngospasm | Very rare (<0.1%) | Vocal cord spasm |

Sample Risk Language: "Common side effects during and shortly after treatment include feeling disconnected from your body or surroundings (dissociation), dizziness, nausea, drowsiness, and temporary increases in blood pressure and heart rate. Most patients experience some dissociation, which is a normal effect of ketamine and typically resolves within an hour after treatment. More serious but rare complications include severe increases in blood pressure, breathing difficulties, prolonged psychological effects, and very rarely, severe allergic reactions. We monitor you closely throughout treatment to manage these risks."

Long-Term and Unknown Risks

| Risk Category | Disclosure | |---------------|------------| | Long-term psychiatric effects | Unknown with repeated low-dose use | | Urinary/bladder effects | Reported with chronic high-dose abuse; unclear with therapeutic use | | Cognitive effects | Unknown with long-term therapeutic use | | Dependence/addiction | Possible; risk factors increase likelihood | | Unknown risks | Treatment is relatively new; unexpected effects may emerge |

Sample Language: "Because ketamine treatment for depression is relatively new, there are uncertainties about long-term effects. Long-term risks known from high-dose chronic ketamine abuse include bladder problems, but it is unclear whether these occur with the lower doses used therapeutically. There is a potential for psychological dependence, especially in those with a history of substance use. We monitor for these issues and will discuss any concerns that arise."

Benefits and Expected Outcomes

Honest Representation:

• Response rates (approximately 60-70% show significant improvement)
• Remission rates (approximately 30-40%)
• Typical timeline of response
• Duration of benefit (variable, often requires maintenance)
• Not everyone responds

Sample Language: "Research shows that approximately 60-70% of patients with treatment-resistant depression experience meaningful improvement with ketamine treatment. Some patients notice improvement within hours to days of their first treatment, though it may take several treatments to see full benefit. The benefits are often temporary, and many patients need ongoing maintenance treatments to sustain improvement. Approximately 30-40% of patients may not respond adequately to ketamine."

Alternatives to Ketamine

Required Disclosure:

• Other medication options
• Other somatic treatments (ECT, TMS)
• Psychotherapy
• Combination approaches
• No treatment / continuing current treatment

Sample Language: "Alternatives to ketamine treatment include: trying additional antidepressant medications or combinations; electroconvulsive therapy (ECT), which is highly effective for treatment-resistant depression but involves anesthesia and potential memory side effects; transcranial magnetic stimulation (TMS), a non-invasive brain stimulation treatment; intensive psychotherapy; or continuing your current treatment plan without adding ketamine. We can discuss any of these alternatives in more detail if you wish."

Right to Refuse or Withdraw

Essential Elements:

• Consent is voluntary
• Patient can refuse treatment
• Patient can stop treatment at any time
• No penalty for refusal or withdrawal
• Ongoing care will continue

Sample Language: "Your decision to undergo ketamine treatment is entirely voluntary. You may refuse to start treatment or stop treatment at any time, even during an infusion, without any penalty and without affecting your ongoing care with us or your other healthcare providers."

Risk Communication Strategies

Health Literacy Considerations

Challenges:

• Medical information is complex
• Patients may be in vulnerable states (depression, anxiety)
• Information overload reduces comprehension
• Technical language creates barriers

Best Practices:

| Strategy | Implementation | |----------|----------------| | Plain language | Use everyday words; define medical terms | | Teach-back method | Ask patient to explain back in their own words | | Written materials | Provide take-home information | | Visual aids | Use diagrams, charts where helpful | | Multiple formats | Verbal, written, video options | | Time | Allow adequate time for discussion | | Repetition | Review key points multiple times |

Balancing Disclosure and Anxiety

The Challenge: Comprehensive risk disclosure may increase patient anxiety, which can be counterproductive for patients with anxiety disorders or who are already anxious about treatment.

Strategies:

Contextualize Risks: "While these side effects are possible, our monitoring and expertise allow us to manage them effectively. Serious complications are rare, and we are prepared to respond if they occur."

Use Comparative Information: "The risk of serious complications from ketamine is lower than from many commonly performed medical procedures."

Emphasize Safeguards: "We monitor your vital signs continuously, have emergency equipment ready, and will stop the treatment immediately if any concerning symptoms develop."

Address Specific Concerns: "What questions or concerns do you have? I want to make sure we address what matters most to you."

Documenting Comprehension

Methods to Document Understanding:

• Patient verbalization of understanding
• Teach-back documentation
• Written acknowledgment of understanding
• Witness to consent discussion
• Video recording (where legally permitted and consented)

Documentation Language: "Patient verbalized understanding of the nature of ketamine treatment, including that it is off-label use, the expected effects and risks, alternatives, and the right to refuse. Patient was given opportunity to ask questions and all questions were answered to patient's stated satisfaction."

Special Consent Considerations

Capacity Assessment

When to Assess Capacity:

• Severe depression affecting cognition
• Presence of psychotic features
• Significant anxiety
• Cognitive impairment
• Prior substance use
• Age extremes

Capacity Elements:

1. Understanding: Can the patient understand the information?
2. Appreciation: Can they appreciate how it applies to them?
3. Reasoning: Can they reason about options?
4. Expression: Can they express a consistent choice?

If Capacity Questionable:

• Document capacity assessment
• Consider formal capacity evaluation
• Involve healthcare proxy if indicated
• Consider postponing treatment until capacity clear

Consent for At-Home Ketamine

Additional Disclosures for Sublingual/At-Home Programs:

| Topic | Disclosure | |-------|------------| | Unsupervised administration | Risks of taking ketamine without medical supervision | | Diversion/sharing | Medication is for patient only; sharing is illegal | | Storage | Secure storage requirements | | Driving/activities | Restrictions around treatment time | | Monitoring protocol | Telemedicine check-ins, symptom tracking | | Emergency situations | When and how to seek emergency care | | Abuse/dependence | Enhanced monitoring and patient responsibility |

Sample Language: "At-home ketamine treatment involves taking medication without direct medical supervision, which carries additional risks compared to in-office treatment. You must store the medication securely, never share it with others, and follow all safety protocols including not driving or operating machinery. You will be monitored through [telemedicine visits/symptom tracking app] and must contact us immediately if you experience any concerning symptoms."

Consent with Support Person Present

Considerations:

• Support person can help patient remember information
• Patient may feel pressured with family present
• Privacy concerns (patient alone should make decision)

Best Practice:

• Offer consent discussion with support person present AND private time for questions/decisions
• Document who was present during consent
• Ensure patient's decision is their own

Renewal of Consent

When to Re-Consent:

• Significant time since initial consent (annually recommended)
• Change in treatment protocol (dose, route, frequency)
• New risks identified
• Patient's condition substantially changed
• After adverse event
• Patient request

Sample Consent Elements

Consent Form Components

Section 1: Introduction

INFORMED CONSENT FOR KETAMINE THERAPY

Patient Name: __________________ DOB: __________
Date: __________

This document describes ketamine therapy for the treatment of [depression/
other indication]. Please read carefully and ask any questions before signing.

Section 2: Diagnosis and Rationale

DIAGNOSIS AND TREATMENT RATIONALE

Your diagnosis is: __________________

Ketamine is being recommended because: __________________

Prior treatments you have tried include: __________________

Section 3: Treatment Description

DESCRIPTION OF TREATMENT

Route of administration: [ ] IV  [ ] IM  [ ] Intranasal  [ ] Sublingual
Planned dose: __________________
Treatment schedule: __________________
Number of treatments planned: __________________

During treatment, you will be monitored by clinical staff in our facility.
You will remain in the treatment area for approximately [time] and must
have a responsible adult to transport you home.

Section 4: Off-Label Disclosure

OFF-LABEL USE DISCLOSURE

[ ] IV/IM/Sublingual Ketamine: FDA approved as an anesthetic; use for
depression is off-label but supported by research evidence

[ ] Esketamine (Spravato): FDA approved for treatment-resistant
depression and acute suicidal ideation in adults with MDD

I understand that "off-label" means the medication is being used for a
purpose other than its original FDA approval, which is a legal and common
practice in medicine.

Patient initials: _____

Section 5: Expected Effects

EXPECTED EFFECTS DURING AND AFTER TREATMENT

During treatment, you may experience:
- Altered perceptions (changes in how things look, sound, or feel)
- Dissociation (feeling detached from your body or surroundings)
- Feeling dream-like or "floaty"
- Difficulty speaking or moving
- Emotional experiences (sometimes profound)

These effects typically resolve within 1-2 hours after treatment.

Patient initials: _____

Section 6: Risks

RISKS OF KETAMINE TREATMENT

Common side effects (occur in more than 10% of patients):
[ ] Dissociation        [ ] Nausea/vomiting
[ ] Dizziness           [ ] Headache
[ ] Elevated blood pressure  [ ] Elevated heart rate
[ ] Fatigue            [ ] Anxiety during treatment

Serious but rare risks (occur in less than 1% of patients):
[ ] Severe blood pressure elevation requiring intervention
[ ] Breathing difficulties
[ ] Prolonged psychological effects
[ ] Allergic reaction

Unknown/long-term risks:
[ ] Long-term effects of repeated treatment are not fully known
[ ] Bladder effects seen with chronic abuse are unclear with therapeutic use
[ ] Potential for psychological dependence exists

Patient initials: _____

Section 7: Benefits

EXPECTED BENEFITS

Research shows:
- Approximately 60-70% of patients experience meaningful improvement
- Approximately 30-40% achieve remission
- Effects may be noticed within hours to days
- Ongoing maintenance treatments are often needed

There is no guarantee of benefit, and some patients do not respond to
ketamine treatment.

Patient initials: _____

Section 8: Alternatives

ALTERNATIVES TO KETAMINE TREATMENT

Alternatives include:
- Additional antidepressant medications
- Electroconvulsive therapy (ECT)
- Transcranial magnetic stimulation (TMS)
- Psychotherapy
- Continuing current treatment without ketamine
- Combination of the above

I have had the opportunity to discuss these alternatives with my provider.

Patient initials: _____

Section 9: Post-Treatment Restrictions

POST-TREATMENT RESTRICTIONS

After ketamine treatment, you must NOT:
- Drive a vehicle for 24 hours
- Operate heavy machinery for 24 hours
- Make important legal or financial decisions for 24 hours
- Consume alcohol for 24 hours

You MUST:
- Have a responsible adult transport you home
- Have someone with you for the remainder of the day

Patient initials: _____

Section 10: Financial Disclosure

FINANCIAL INFORMATION

[ ] This treatment is unlikely to be covered by insurance due to off-label
    status. The cost per treatment is approximately $_______.

[ ] This treatment (Spravato) may be covered by insurance. We will assist
    with prior authorization. Out-of-pocket costs depend on your coverage.

I understand my financial responsibility for this treatment.

Patient initials: _____

Section 11: Questions and Voluntary Agreement

QUESTIONS AND AGREEMENT

I have had the opportunity to ask questions about ketamine treatment.
All my questions have been answered to my satisfaction.

My questions included: __________________

I understand that I may refuse treatment or stop treatment at any time
without penalty.

I voluntarily consent to ketamine therapy as described in this document.

_________________________  __________
Patient Signature          Date

_________________________  __________
Provider Signature         Date

_________________________  __________
Witness Signature          Date

Documentation Template

CONSENT DISCUSSION DOCUMENTATION

Date: __________
Patient: __________
Provider: __________

Duration of consent discussion: _____ minutes

Topics discussed:
[ ] Diagnosis and treatment rationale
[ ] Treatment description (route, dose, frequency, setting)
[ ] Off-label status and implications
[ ] Expected effects during treatment
[ ] Common side effects
[ ] Serious but rare risks
[ ] Long-term and unknown risks
[ ] Expected benefits and limitations
[ ] Alternative treatments
[ ] Post-treatment restrictions
[ ] Financial responsibility
[ ] Right to refuse/withdraw
[ ] Questions and answers

Patient questions addressed:
_________________________________________________
_________________________________________________

Assessment of patient understanding:
[ ] Patient verbalized understanding of key elements
[ ] Patient demonstrated understanding through teach-back
[ ] Patient appeared to understand and engage appropriately
[ ] Concerns about understanding (explain): __________

Capacity assessment:
[ ] Patient demonstrated capacity to consent
[ ] Capacity formally assessed due to: __________
[ ] Capacity concerns (explain): __________

Support persons present (if any): __________

Written consent form:
[ ] Reviewed with patient
[ ] Patient signed voluntarily
[ ] Witness signed
[ ] Copy provided to patient

Provider signature: __________
Date: __________

Legal Considerations

Standard of Care

Informed consent must meet the applicable standard:

"Reasonable Physician" Standard: What would a reasonably prudent physician disclose under similar circumstances?

"Reasonable Patient" Standard: What would a reasonable patient want to know to make an informed decision?

Trend: Most jurisdictions moving toward patient-centered standard.

Best Practice: Disclose what a reasonable patient would want to know, tailored to individual patient concerns and questions.

Documentation as Defense

In malpractice litigation, documented informed consent:

• Demonstrates duty of disclosure was met
• Shows patient was informed of risks that materialized
• Provides evidence of patient's voluntary agreement
• Supports claim that patient assumed known risks

Documentation Best Practices:

• Contemporaneous documentation
• Specific details of discussion
• Patient's questions and answers given
• Patient's verbalized understanding
• Witness when possible
• Signed consent form

State-Specific Requirements

Research requirements in your state for:

• Specific disclosures required by statute
• Witnessing requirements
• Capacity standards
• Surrogate decision-making rules
• Consent for specific treatments/procedures
• Minor consent and assent

Consent and Malpractice Insurance

Considerations:

• Verify insurer's requirements for consent documentation
• Confirm coverage for off-label use
• Ensure consent addresses off-label status
• Document per insurer guidelines
• Report claims promptly

Clinical Takeaways

1. Consent Is a Process: View informed consent as an ongoing dialogue, not just a signature event. Build understanding through conversation, not just documents.

2. Off-Label Disclosure Is Essential: Clearly explain what off-label use means, why it is appropriate, and its implications. This protects both patient autonomy and practitioner liability.

3. Balance Thoroughness and Anxiety: Provide complete risk information while contextualizing risks and emphasizing safeguards. Anxious patients still need accurate information.

4. Document Comprehensively: Document not just that consent was obtained, but the substance of the discussion, patient's questions, and evidence of understanding.

5. Tailor to the Individual: While using standard consent elements, address each patient's specific concerns and ensure the consent reflects their unique situation.

6. Re-Consent When Indicated: Treatment changes, significant time passage, and adverse events warrant renewed consent discussions.

7. Verify Capacity: For patients whose capacity may be affected by their condition, document capacity assessment or involve appropriate resources.

8. Use Plain Language: Complex medical information must be communicated in language patients can understand. Use teach-back to verify comprehension.

Informed consent for ketamine therapy requires thoughtful attention to the unique aspects of this treatment modality. By approaching consent as a patient-centered process focused on shared decision-making, practitioners honor their ethical obligations while establishing the foundation for a successful therapeutic relationship.

References

1. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 8th ed. Oxford University Press; 2019.
2. Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972).
3. American Medical Association. Informed Consent. Code of Medical Ethics Opinion 2.1.1.
4. Appelbaum PS, Grisso T. Assessing patients' capacities to consent to treatment. N Engl J Med. 1988;319(25):1635-1638.
5. FDA. "Off-Label" and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices. FDA Guidance. 1998.